Pharmacogenomic analysis of individual variation in prostate cancer

Abstract

Single Nucleotide Polymorphisms (SNPs) are the most common genetic variation among individuals. The work aims at identifying the SNPs associated with prostate cancer. In the present work, pharmacogenomic analysis has been carried out to analyze the impact of functional SNPs in prostate cancer. 11 genes involved in signal transduction in prostate cancer have been subjected to genomic analysis. The genomic analysis protocol includes microsatellite analysis, restriction fragment length polymorphism (RFLP) analysis, silent mutation analysis, GC content Analysis and deleterious SNP analysis. From the deleterious SNP analysis, it has been found that the mutations rs28571178 in IL16 (5’ UTR) and rs17854206 in JAZF1 (3’ UTR) cause functional effects on the specific genes. Upon stability analysis of native and mutated proteins, it has been concluded that the above deleterious mutations are supported by nature due to their increased stability. These SNPs have been identified as the most deleterious in causing prostate cancer.